Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Preferred Shares: 2016-2017

  • UroGen Pharma's Preferred Shares fell 100.66% to -$3,780 in Q3 2017 from the same period last year, while for Sep 2017 it was -$3,780, marking a year-over-year decrease of 100.66%. This contributed to the annual value of $13,000 for FY2016, which is N/A change from last year.
  • Latest data reveals that UroGen Pharma reported Preferred Shares of -$3,780 as of Q3 2017, which was down 100.08% from $4.7 million recorded in Q2 2017.
  • In the past 5 years, UroGen Pharma's Preferred Shares registered a high of $4.7 million during Q2 2017, and its lowest value of -$3,780 during Q3 2017.
  • In the last 2 years, UroGen Pharma's Preferred Shares had a median value of $291,500 in 2016 and averaged $1.3 million.
  • Data for UroGen Pharma's Preferred Shares shows a maximum YoY plummeted of 100.66% (in 2017) over the last 5 years.
  • Over the past 2 years, UroGen Pharma's Preferred Shares (Quarterly) stood at $13,000 in 2016, then plummeted by 100.66% to -$3,780 in 2017.
  • Its Preferred Shares stands at -$3,780 for Q3 2017, versus $4.7 million for Q2 2017 and $13,000 for Q4 2016.